SUPN News and Press, Supernus Pharmaceuticals Inc. From 08/07/22

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2022 Earnings Conference Call August 4, 2022 16:30 ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Particip...

Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q2 GAAP EPS of $0.14 misses by $0.15 . Revenue of $170.05M (+674.0% Y/Y) beats by $5.82M . Outlook 2022: Total revenues $640M - $680M. Consensus $674.55M. Operating earnings $20M - $40M ...

Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021 Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating earnings of $37.6 million Qelbree ® continued its growth trajectory, w...

Supernus Pharmaceuticals' newly approved QELBREE indication is poised to enhance its revenues. Supernus' developing Parkinson's disease [PD] franchise, with its upcoming PDUFA, is an uncertain catalyst. After a mixed Q1, 2022, expect Q2 to be uneventful, with deals likely looming ...

ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fina...

ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of...

BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler J...

Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q1 GAAP EPS of $0.43 misses by $0.02. Revenue of $152.51M (+16.5% Y/Y) beats by $2.04M. Non-GAAP operating income of $28.0 million. U.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adults. Qelbree&...

First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021 First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively First quarter 2022 GAAP operating income of $2.0 million; first ...